Stock PUR PURE BIOLOGICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Pure Biologics S.A. Stock

Equities

PUR

PLPRBLG00010

Biotechnology & Medical Research

Delayed Warsaw S.E.
Other stock markets
 03:02:06 2024-05-24 am EDT 		5-day change 1st Jan Change
7.68 PLN 0.00% Intraday chart for Pure Biologics S.A. +2.40% -39.24%
2023 Pure Biologics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Pure Biologics S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Financials

Sales 2021 254K 64.44K Sales 2022 662K 168K Capitalization 51.84M 13.15M
Net income 2021 -11M -2.79M Net income 2022 -25M -6.34M EV / Sales 2021 573 x
Net cash position 2021 29.82M 7.56M Net cash position 2022 4.32M 1.1M EV / Sales 2022 71.8 x
P/E ratio 2021
-14.7 x
P/E ratio 2022
-2 x
Employees 96
Yield 2021 *
-
Yield 2022
-
Free-Float 82.58%
More Fundamentals * Assessed data

Chart Pure Biologics S.A.

Dynamic Chart

Latest news about Pure Biologics S.A.

Pure Biologics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Pure Biologics S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Presage Announces Collaboration with Pure Biologics to Investigate Oncology Agents in Early Development with CIVO® Technology CI
Dom Maklerski Navigator S.A. and IPOPEMA Securities S.A. agreed to acquire an unknown minority stake in Pure Biologics Spólka Akcyjna. CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Pure Biologics Sp?lka Akcyjna Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Pure Biologics Spólka Akcyjna Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Pure Biologics Spólka Akcyjna announced that it has received €6.7 million in funding from National Centre for Research and Development CI
Pure Biologics Spólka Akcyjna announced that it has received PLN 10.1 million in funding CI
More news

Quotes and Performance

1 week+2.40%
Current month-2.17%
1 month-1.54%
3 months-15.88%
6 months-24.26%
Current year-39.24%
More quotes

Highs and lows

1 week
7.40
Extreme 7.4
8.27
1 month
7.01
Extreme 7.01
8.27
Current year
6.95
Extreme 6.95
16.98
1 year
5.01
Extreme 5.01
21.90
3 years
5.01
Extreme 5.01
117.40
5 years
5.01
Extreme 5.01
152.00
10 years
5.01
Extreme 5.01
152.00
More quotes

Managers and Directors - Pure Biologics S.A.

Managers TitleAgeSince
Maciej Piotr Mazurek FOU
 Founder - 09-12-31
Filip Jan Jelen CEO
 Chief Executive Officer 47 09-12-31
Romuald Harwas DFI
 Director of Finance/CFO 52 19-12-15
Members of the board TitleAgeSince
Tadeusz Wesolowski BRD
 Director/Board Member 72 19-05-06
Andrzej Jan Trznadel FOU
 Founder 62 09-12-31
Pawel Marcin Wisniewski BRD
 Director/Board Member 44 23-05-25
More insiders

Quotes

Date Price Change Volume
24-05-24 7.68 0.00% 111
24-05-23 7.68 +0.92% 5,953
24-05-22 7.61 -4.87% 21,433
24-05-21 8 +8.11% 10,452
24-05-20 7.4 -1.33% 8,043

Delayed Quote Warsaw S.E., May 24, 2024 at 03:02 am EDT

More quotes

Company Profile

Pure Biologics SA is a manufacturer of biological products. The Company was founded in August 2010 and is located in Wroclaw, Poland.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PURE BIOLOGICS S.A. Stock Pure Biologics S.A.
-39.24% 6.49M
MODERNA, INC. Stock Moderna, Inc.
+64.92% 62.86B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.85% 41.38B
LONZA GROUP AG Stock Lonza Group AG
+45.32% 40.38B
CELLTRION, INC. Stock Celltrion, Inc.
-8.93% 27.64B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.05% 26.46B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.96% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.21% 12.67B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.74% 12.27B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.42% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PUR Stock